Close Close
Sign In
Newsletters
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
Podcast Center Video Center Webcasts Resource Center Events
About ThinkAdvisor Contact Us Advertise With Us Asset & Logo Licensing Sitemap Terms of Service Privacy Policy Copyright © 2024 ALM Global, LLC. All Rights Reserved.
ThinkAdvisor

Life Health > Annuities > Variable Annuities

VA Sales Soared 14.7% In First 9 Months

By Frank Oconnor

X
Your article was successfully shared with the contacts you provided.

Third quarter variable annuity new sales of $45.2 billion were down slightly from the peak level of $46.5 billion reached in the 2nd quarter, although year-to-date sales of $132.1 billion are still a healthy 14.7% higher than 3rd quarter 2006 year-to-date sales of $115.2 billion.

Net flow dropped to $9.1 billion in the third quarter from a revised $9.2 billion in the 2nd quarter. This is not a large change, and only a 1.1% decrease in net flow during a period when sales fell by 2.7%, which is certainly preferable to a matching decline in both metrics.

Total sales in 2007 should be about $180 billion, with net flow for the year reaching $34 billion, or an approximately 15% increase in both of these important industry barometers.

Assets also rose to just shy of the $1.5 trillion mark to close the quarter at $1,492.8 billion, a 2.7% increase over 2nd quarter assets of $1,454.0 billion and up 9.4% from assets as of the end of 2006 totaling $1,364.3 billion.

MetLife once again took the top spot in sales, for both the quarter and year-to-date periods, but AXA Equitable was right behind. On a year-to-date basis, the top 5 companies were MetLife with a market share of 8.8%; AXA Financial (8.6%); TIAA-CREF (8.0%); Hartford Life (7.7%); and Lincoln National (6.9%).

The top 5 non-group products so far this year have been the RiverSource RAVA4 Advantage with 3.3% of year-to-date sales; Jackson National Perspective II (2.9%); John Hancock Venture III (2.8%); Pacific Life Innovations Select (2.5%); and American Skandia Xtra Credit Six (1.9%).

For the 3rd quarter the results were a bit different, with Venture III in the lead spot at a market share of 3.1%, followed by RAVA4 Advantage (3.0%); Perspective II (2.9%); Innovations Select (2.5%); and Accumulator Elite 2007 (2.1%).

When using these tables to gain insight on top selling products, it is important to note the effect of product closings and new product launches on the statistics from different time periods. For example, the appearance of Accumulator Elite in the quarterly top 5 but not in the year-to-date rankings is the result of a substantial portion of the year-to-date sales being allocated to the Accumulator Elite 2006 product, to which sales prior to the May launch of Elite 2007 were allocated.

As of this writing, 2007 VA sales are expected to reach or exceed $180 billion, an approximately 15.6% increase over 2006 sales of $157.3 billion and a staggering 56.5% higher than VA sales 5 years ago, when 2002 full year sales totaled $115 billion.

Throughout those years, various sources, some statistical, some anecdotal, have attributed 50% or more of variable annuity sales to exchanges of existing variable annuities for new contracts, with some studies putting exchange volume as high as 85% of total sales. While a comprehensive, authoritative study of exchange levels over time has not, to date, been conducted, in large part due to the difficulty obtaining complete and accurate data, postulating an industry-wide exchange rate of 40% is not unreasonable.

Exchanges are an area of particular interest to the Financial Industry Regulatory Authority (FINRA), and as such are subject to particularly stringent review requirements under the new Variable Annuity Suitability Rule, NASD 2821, which becomes effective May 5, 2008. Principal review of annuity exchanges must consider not only the efficacy of the exchange on an objective, “is this good for the client” basis, but must also consider recent prior exchanges, and more generally must monitor associates based on the rate of exchanges they are performing.

It is reasonable to expect a reduction in the volume of exchanges as a result of this new regulation, but the unanswered question concerns the impact on VA sales. Will sales plummet, fueling the rhetoric that the variable annuity industry has been largely recycling old business for years? Will new money in the form of boomer qualified plan rollover dollars continue to flow into variable annuity living benefits, offsetting the effects of a significant reduction exchanges? Or will everything go on substantially as before in spite of the new regulation?

NASD 2821 will certainly make it more difficult to transact VA business, and will add additional challenges to the a crucial dilemma facing this industry, namely how to get advisors working with retirees and near-retirees who don’t sell the product today to give it another look as the needs of their older client shift. In that respect NASD 2821 may be a blessing in disguise, forcing the industry to focus more attention on educating advisors and investors about the product, and continuing to invest in tools and support for advisors.

Wholesaler support–not just product positioning and promotion but pointed advice on growing and sustaining a practice through the appropriate use of variable annuities–will be crucial in this new environment, as will conceptual educational materials, illustration tools and product evaluation software.

Frank O’Connor is product manager, VARDS, at Morningstar, Inc. He can be reached via email at .

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.